GAT BIOSCIENCES S.L.
- Biotech or pharma, therapeutic R&D
GATBIO is a biotech devoted to delivering oral biologic therapies for intestinal inflammatory diseases. Our mission is the accessibility of oral biologics, replacing current costly injected biologics with daily oral pills solutions.
GATBIO has developed and patented a new class of antibodies stable to temperature and harsh intestinal atmosphere for their oral administration and local/restricted action in damaged intestinal tissues. This technology allows GATBIO to propose much more efficient and safer biological therapies for IBD, for long-term use minimizing systemic related side effects and drug rejection issues of injected alternatives.
GB-AF-004 - GATBIO’s lead candidate (preclinical stage) - is an efficient inflammation blocker orally delivered to the damaged intestinal tissues to act locally/restrictively. Our portfolio targets key players in the intestinal inflammatory cascade for long-term, safer and personalized next-gen IBDs therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}